PT  - JOURNAL ARTICLE
AU  - Barcia, Giulia
AU  - Rio, Marlène
AU  - Assouline, Zahra
AU  - Zangarelli, Coralie
AU  - Roux, Charles-Joris
AU  - de Lonlay, Pascale
AU  - Steffann, Julie
AU  - Desguerre, Isabelle
AU  - Munnich, Arnold
AU  - Bonnefont, Jean-Paul
AU  - Boddaert, Nathalie
AU  - Rötig, Agnès
AU  - Metodiev, Metodi D.
AU  - Ruzzenente, Benedetta
TI  - Novel <em>FARS2</em> variants in patients with early onset encephalopathy with or without epilepsy associated with long survival
AID  - 10.1101/2019.12.30.19016139
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2019.12.30.19016139
4099  - http://medrxiv.org/content/early/2020/09/17/2019.12.30.19016139.short
4100  - http://medrxiv.org/content/early/2020/09/17/2019.12.30.19016139.full
AB  - Mitochondrial translation is essential for the biogenesis of the mitochondrial oxidative phosphorylation system (OXPHOS) that synthesizes the bulk of ATP for the cell. Hypomorphic and loss-of-function variants in either mitochondrial DNA or in nuclear genes that encode mitochondrial translation factors can result in impaired OXPHOS biogenesis and mitochondrial diseases with variable clinical presentations.Compound heterozygous or homozygous missense and frameshift variants in the FARS2 gene, that encodes the mitochondrial phenylalanyl-tRNA synthetase, are commonly linked to either early-onset epileptic mitochondrial encephalopathy or spastic paraplegia. Here, we expand the genetic spectrum of FARS2-linked disease with three patients carrying novel compound heterozygous variants in the FARS2 gene and presenting with spastic tetraparesis, axial hypotonia and myoclonic epilepsy in two cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant Numbers: AFM-TELETHON, nr. 19876, nr. 22529, nr. 22251; ANR, GENOMIT ANR-15-RAR3-0012-07Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request. Variants were submitted to ClinVar